Loading…

MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in high grade serous ovarian cancer

Saved in:

Bibliographic Details
Published in:	Clinical cancer research 2015-10, Vol.22 (4), p.935-947
Main Authors:	Hew, Karina E., Miller, Philip C., El-Ashry, Dorraya, Sun, Jun, Besser, Alexandra H., Ince, Tan A., Gu, Mengnan, Wei, Zhi, Zhang, Guo, Brafford, Patricia, Gao, W., Lu, Yiling, Mills, Gordon B., Slingerland, Joyce M., Simpkins, Fiona
Format:	Article
Language:	English
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!